Finance entity
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Grail, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Last mentioned: Mar 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Grail, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. Their average consequence score of 6 runs below the beat's 6.5 for that window. We currently track 1 Finance story that mention Bob Ragusa, all published on March 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 71 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bob Ragusa. Shared-story counts are live from our verified record — not editorial picks.
Market Outperformance
Financial media highlights Grail as the week's top performer in the diagnostics sector.
Volume Surge
Stock sees highest trading volume in six months as institutional buyers return.
TD Cowen Upgrade
Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals.
Market Low
GRAL stock hits a 52-week low amid heavy selling pressure.
CEO Transition
Bob Ragusa steps down as CEO following reports of a trial setback.
Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
Bob Ragusa is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
